5 Nov 2015 07:00
5 November 2015
AIM: REDX
REDX PHARMA PLC
("Redx" or "the Group")
Senior management appointments
Redx, the drug discovery and development company, is pleased to announce two senior management appointments, with Nicholas Adams joining as Chief Business Officer and Dr Matilda Bingham's promotion to Executive Director of Redx Oncology Ltd, the Group's oncology subsidiary.
Nicholas Adams's role as Chief Business Officer is a newly developed position and his appointment commences on 19 November. Nick has over 25 years' experience in the pharmaceutical industry, and in particular in business development. He has led a wide range of deal types, including in- and out-licensing, divestments, royalty buy-outs as well as M&A. He has also worked in clinical development in large and mid-sized pharmaceutical companies and in biotech. Most recently, he was Chief Business Officer of Clavis Pharma ASA, the Norwegian drug development company specialising in oncology. Prior to that, he was Vice President of Business Development at Antisoma Research plc, which developed therapies for cancer and autoimmune disease.
Dr Matilda ("Tilly") Bingham has been appointed as Executive Director of Redx Oncology Ltd, with immediate effect, having served as Interim Managing Director of the subsidiary. She joined Redx in 2012 from MSD Research Laboratories, part of Merck & Co., Inc., where she led the medicinal chemistry teams. She has over 13 years of experience in the pharmaceutical industry, with a track record of delivering clinical development candidates.
Neil Murray, Chief Executive of Redx, commented:
"We are delighted to announce the appointments of Nick and Tilly to our executive management team. Nick brings extensive experience in business development roles as well as a strong clinical background. I am equally pleased that Tilly has been promoted to the position of Executive Director of Redx Oncology. She has been a valued member of the team since 2012, with a track record of delivery across the organisation.
These appointments are part of Redx's growth strategy and will help to accelerate the Group's next phase of development as a commercially driven drug discovery and development company."
For further information, please contact:
Redx Pharma Plc |
| T: 0151 706 4747 |
Neil Murray, Chief Executive Company website: redxpharma.com |
|
|
KTZ Communications |
| T: 020 3178 6378 |
Katie Tzouliadis |
|
|
About Redx Pharma Plc
www.redxpharm.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 13 proprietary (patent‑protected) drug programs. Five programs have now achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.